Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism

26 August 2010, 5:00 am

SAN DIEGO, CA--(Marketwire - 08/26/10) - Cypress Bioscience, Inc. (NASDAQ: CYPB - News ), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, today announced that it has acquired patent rights and technology related to a novel, intranasal formulation of carbetocin, a potential breakthrough treatment for the core symptoms of ...... Read More »

More Topics from "News"

• Laird wins Eastern League MVP and ROY awards
• 9/3 Steppin' Out
• Prince George County Public Schools
• Daily Dose: 09/02/10
• Intel CEO: U.S. faces looming tech decline
• Alzheimer's Therapeutics Reviewed by NeuroInvestment
• Back Burner: Sept. 1, 2010
• Best of the West: National park beaches
• Sonoma Co. leases & sales: Week of Aug. 30, 2010